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Abstract 
Background: "Triple-negative breast cancers" (TNBC) comprise a heterogeneous group of about 15% of 
invasive BCs lacking the expression of estrogen and progesterone receptors (ER, PR) and the expression of 
HER2 (ERBB2) and are therefore no established candidates for targeted treatment options in BC, i.e., 
endocrine and anti-HER2 therapy. The aim of the present study was to use gene expression profiling and 
immunohistochemical (IHC) characterization to identify receptor tyrosine kinase (RTK) profiles that would 
allow patient stratification for the purposes of target-oriented personalized tumor therapy in TNBC. 
Methods: Twenty-nine cases of TNBC selected according to routine diagnostic IHC/cytogenetic criteria were 
examined by reverse transcription polymerase chain reaction (RT-PCR). RTK mRNA expression profiles were 
generated for a total of 31 tumor-relevant biomarkers, mainly belonging to the IGF- and EGF-receptor families 
but also including biomarkers related to downstream signaling. Protein expression of selected biomarkers was 
investigated by IHC.  
Results: Hierarchical cluster analysis revealed a dichotomous differentiation pattern amongst TNBCs. A 
significant difference in gene expression was observed for 16 of the 31 RTK-associated tumor relevant 
biomarkers between the two newly identified TNBC subgroups. The findings were verified at the 
posttranslational level by the IHC data. The RTKs HER4, IGF-1R and IGF-2R and the hormone receptors ER 
and PR below the IHC detection limit play a central role in the differentiation of the two TNBC subgroups. 
Observed survival was reported as Kaplan-Meier estimates and point towards an improved survival of patients 
with RTK-high with superior three-year survival rate of 100% compared to RTK-low gene signatures with 
superior three-year survival rate of 60% (log-rank test, p-value = 0.022). 
Conclusion: Gene-expression and IHC analysis of the EGF and IGF receptor families and biomarkers 
associated with downstream signaling point to the existence of two distinct TNBC subtypes. The RTKs HER4, 
IGF-1R, IGF-2R and the hormone receptors ER and PR appear to be of particular importance here. Based on 
survival analysis the differentiation of TNBC with RTK-high and RTK-low gene signatures seems to be of 
prognostic relevance. Additionally, correlation analysis of the relationship between RTKs and ER suggests 
co-regulatory mechanisms that may have potential significance in new therapeutic approaches. 
Key words: triple-negative breast cancer, subtyping, personalized tumor therapy, Real-Time RT-PCR, receptor 
tyrosine kinase (RTK), RTK-high gene signature, RTK-low gene signature 
Introduction 
About one in eight women will be diagnosed 
with breast cancer during their lifetime, making this 
the most frequent malignant diseases in women [1]. 
Figures published by the WHO indicate that, 
worldwide, about 1,000,000 women develop breast 
cancer every year. Breast cancer comprises a 
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heterogeneous group of malignant diseases that can 
be differentiated primarily on the basis of 
histopathological criteria into several distinct 
sub-groups of varying incidences [2]. 
Intense research efforts in recent years have 
provided insight into a large number of the complex 
molecular mechanisms involved in the pathogenesis 
of breast cancer [3]. Current attempts to develop 
individualized tumor therapies are aimed at 
identifying and treating further distinct subtypes on 
the basis of therapeutically relevant surrogate 
markers [4, 5, 6, 7, 8]. In addition to the classical 
histopathological parameters, the IHC 
characterization of hormone receptor status and 
HER2 as well as when indicated the cytogenetic 
detection of HER2 gene amplification represent the 
first important parameters upon which 
individualized tumor-specific therapy for breast 
carcinoma can be based. About 85% of all breast 
cancer patients currently receive such individualized 
therapy, which is aimed at the inhibition of HER2 
(Trastuzumab, Lapatinib) and estrogen receptors 
(Tamoxifen, Letrozol) and is now considered standard 
treatment [9].  
Thus, breast carcinoma can be roughly divided 
into tumors that are positive for 
estrogen/progesterone receptors and/or HER2 
(triple-positive) which are suited to established, 
personalized therapy and those that are negative for 
these markers (triple-negative) without such benefit.  
Triple-negative tumors are primarily defined, 
therefore, by an absence of surrogate markers of 
relevance for individualized therapy. As has been 
shown in numerous studies, triple-negative tumors 
vary in tumor progression, the development of 
therapeutic resistance, and the clinical course [10, 11, 
12, 13, 14, 15], which indicates that they comprise a 
heterogeneous group. Further characterization and 
subtyping of triple-negative tumors on the basis of 
therapeutically relevant biomarkers is therefore 
strongly necessary.  
To this end, a number of international 
microarray and NGS studies have produced data on 
the characterization of triple-negative tumors at the 
molecular level [13, 16, 17, 18]. In addition, further 
attempts to subtype these tumors have differentiated 
between basal-like and myoepithelial tumors [19, 20, 
21] the findings being primarily of prognostic 
relevance. However, little therapeutic strategies 
targeting basal-like tumor cell specific surrogate 
markers have yet been developed. 
The search for new approaches to individualized 
therapy during recent years has revealed biomarkers 
with predictive relevance for a large number of 
malignant diseases, which have been used in the 
development of individualized tumor therapy 
modalities in clinical trials. Various RTK families are 
of particular importance here. The treatment success 
achieved with trastuzumab (Herceptin) in HER2+ 
breast cancer has stimulated a search for other 
therapeutic targets including other members of 
elements of the epidermal growth factor receptor 
(EGFR) family. 
The concept of growth factor receptor based 
anti-tumor therapy has been investigated and 
developed in recent years, especially in relation to 
EGFR. This has produced a series of EGFR inhibitors 
that have been approved for the treatment of 
epithelial tumors. In addition to the therapeutic 
monoclonal antibodies cetuximab and panitumumab, 
which are of great importance in the treatment of 
colorectal carcinoma, antineoplastic effects have been 
demonstrated for the receptor tyrosine kinase 
inhibitors (RTKI) gefitinib (Iressa) and erlotinib 
(Rarceva) in non-small cell lung cancer and for 
lapatinib (Tykerb) in metastatic breast cancer [22, 23, 
24].  
In addition to the representatives of the EGF 
receptor family, insulin-like growth factor receptor 1 
(IGF-1R) is a further promising candidate for the 
development of individual therapeutic approaches in 
oncology. Various specific therapeutic monoclonal 
antibodies and RTKI against IGF-1R, growth factor 
antagonists and IGF-1R are currently undergoing 
clinical trials [25, 26, 27]. 
The aim of the present study was, by means of 
gene expression analysis and IHC investigations, to 
identify various RTK of the EGFR and IGFR families 
that would enable patient stratification for the 
purposes of target-oriented individualized tumor 
therapy in TNBC. In addition, correlation analysis 
was undertaken to shed light on possible interactions 
amongst the various RTK and provide a basis for 
innovative approaches to individualized tumor 
therapy.  
Materials and Methods 
Patients and tumors  
A total of 29 triple-negative invasive ductal 
breast carcinomas, which had been diagnosed in the 
course of routine histopathological investigation at 
the Institute of Pathology, Ludwig-Maximilians- 
Universität Munich during the years 2003 to 2005, 
were selected for investigation. All tumors were 
re-determined for negative hormone receptor and 
negative HER2 status according to up-to-date 
histopathological guidelines and recommendations 
[28, 29]. ER and PR negativity was defined as positive 
staining in <1% of tumor cells. HER2 negativity was 
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defined as an IHC score of 0 or 1+; those with an 
immunoreactive score of 2+ underwent HER2-specific 
FISH analysis to exclude HER2 gene amplification. 
Further selection criteria included the high-risk 
parameters of high tumor grade (grade 3) and low age 
(cut-off of ≤ 55 years) at primary manifestation of 
disease (average age 41 years; x = 41.3 years; s = 7.8 
years) at the time of diagnosis. Tumor size was 
documented in relation to the patient specific 
chemotherapeutic treatment regimen before adjuvant 
respectively before neoadjuvant chemotherapeutic 
treatment. The mean tumor size was 3.3 cm (x = 3.3 
cm, s = 3.5 cm). Nineteen patients received adjuvant 
chemotherapy and 9 patients neoadjuvant 
chemotherapy. Within the observation time of this 
study recurrence rate was 24% for patients treated 
with adjuvant chemotherapy and 63% for patients 
with neoadjuvant treatment. None of the patiens with 
neoadjuvant chemotherapy showed a pathological 
complete response (pCR). Tumors in 6 patients 
showed an infiltration of lymph or blood vessels 
(lymphangiosis-, hemangiosis carcinomatosa) at the 
time of diagnosis and one patient had distant 
metastases. Details of the diagnostically relevant 
parameters in the study group are given in Table 1. 
Material investigated 
The investigations were performed on 
formalin-fixed, paraffin-embedded tissue (FFPET) 
processed for routine histopathological diagnostic 
investigation. All analyses were performed at 
resection specimens. 
Deparaffinisation and RNA extraction 
For each case, nine 4-µm FFPET whole sections 
comprising more than 70% tumor were cut and 
deparaffinized according to standard protocols. Total 
RNA was isolated by means of a commercial RNA 
isolation kit (High-Pure RNA Isolation Kit, Roche). 
RNA samples were analyzed photometric for their 
qualitative and quantitative content (NanoDrop, 
Thermo Scientific, USA). The minimum RNA content 
required for gene expression analysis was 300 ng/µl 
(total volume: 45 µl). An adequate amount of total 
RNA could be isolated from a total of 29 of the 31 
triple-negative tumors that were initially selected for 
investigation. 
cDNA synthesis 
cDNA synthesis was performed by 
primer-specific reverse transcription of total RNA 
according to a standard protocol (Transkriptor First 
Strand cDNA Synthesis Kit, Roche). In brief, 3 µl RNA 
(50 ng/µl), 1 µl sequence-specific primer (1 µM), 9 µl 
distilled water, 4 µl 5X buffer, 2 µl nucleotide mix 
(each 10 mM), 0.5 µl protector RNase inhibitor (40 
U/µl) and 0.5 µl transcriptor reverse transcriptase (20 
U/µl) per reaction were mixed, preincubated for 10 
minutes at 95°C and incubated for one hour at 50°C. 
 
Table 1. Diagnostically relevant parameters in the study group 
Case Age Grade Estrogen Progesterone HER2/ 
neu 
Lymph 
nodes 
Tumor 
size (cm)  
Lymphangiosis carcinomatosa / 
Angiosis carcinomatosa 
Neoadjuvant 
chemo-therapy 
Adjuvant 
chemo-therapy 
Distant 
metastases 
1 42 3 0 0 0 0 2.3     x   
2 31 3 0 0 1+ 1 1.6 x x     
3 43 3 0 0 0 1 1.5     x   
4 42 3 0 0 0 0 1.1     x   
5 53 3 0 0 0 0 1.3     x   
6 38 3 0 0 1+ 0 1.6     x   
7 45 3 0 0 0 1 15 x   x   
8 48 3 0 0 1+ 0 2.5 x x     
9 28 3 0 0 1+ 0 1.9     x   
10 42 3 0 0 0 0 nd x x     
11 34 3 0 0 0 nd 3.3   x     
12 31 3 0 0 0 1 3.6   x     
13 47 3 0 0 0 nd nd   nd nd   
14 53 3 0 0 0 0 4.3     x   
15 34 3 0 0 0 1 2.2     x   
16 51 3 0 0 0 0 0.7     x   
17 40 3 0 0 0 0 2.2     x   
18 49 3 0 0 0 nd 0.9     x   
19 53 3 0 0 0 1 2.5   x   x 
20 51 3 0 0 2+ 0 5   x     
21 35 3 0 0 2+ 1 3 x x     
22 49 3 0 0 1+ 0 2.1     x   
23 43 3 0 0 1+ 1 2 x   x   
24 35 3 0 0 0 0 2   x     
25 33 3 0 0 2+ 0 2.6     x   
26 41 3 0 0 1+ 0 10     x   
27 32 3 0 0 0 0 2.5     x   
28 30 3 0 0 0 1 2     x   
29 46 3 0 0 0 0 5     x   
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Per 96-well plate a standard dilution series 
(dilution factor 1:5), calibrator, negative control and 
29 tumor samples were processed. A total of 34 
biomarkers, including representatives of the EGFR 
and IGF-1R families and biomarkers related to 
downstream signaling, and five housekeeping genes 
(HKG) were analyzed in separate runs. 
PCR Amplification 
Gene expression data were obtained using 
sequence-specific detection probes (hydrolysis 
probes). With the help of the Universal ProbeLibrary 
Software [30], primer-specific sequences and 
target-specific hydrolysis probes for 34 biomarkers 
and 5 HKG were determined on the basis of freely 
accessible data banks (Table 2). 
 
Table 2. Biomarkers / Universal ProbeLibrary Assays 
Biomarker Primersequence (5' -> 3'-direction) Probe No. Reverse Primer RT 
EGFR Fwd cat gtc gat gga ctt cca ga 44 ttc tcc tct cct gca cc 
EGFR Rev1 ggg aca gct tgg atc aca ct 
HER2 Fwd tgg ctc agt gac ctg ttt tg 75 tca ggt ttc aca ccg ct 
HER2 Rev1 ggt cct tat agt ggg cac agg 
Her3 Fwd cac aat gcc gac ctc tcc 86 tgg gca atg gta gag tag ag 
Her3 Rev1 cac gag gac ata gcc tgt ca 
Her4 Fwd ttc cac ttt acc aca aca tgc ta 78 aca gca aat gtc aga ccc 
Her4 Rev1 cag aat gaa gag ccc acc a 
TGF-alpha Fwd tgc tgc cac tca gaa aca gt 63 agt gct gtc ctg aag aag c 
TGF-alpha Rev1 atc tgc cac ag tcc acc tg 
EGF Fwd tgg ttg tgg ttc atc cat tg 68 tca cag cct ccg ttt tga ta 
EGF Rev1 tca cag cct ccg ttt tga ta 
beta-cellulin Fwd act gca tca aag gga gat gc 49 acc ttg ctc caa tgt agc 
beta-cellulin Rev1 tcc aat gta gcc ttc atc aca 
Amphiregulin Fwd cgg aga atg caa ata tat aga gca c 38 tgt caa tca tgc tgt gag ttt 
Amphiregulin Rev1 cac cga aat att ctt gct gac a 
HB-EGF Fwd tgg ggc ttc tca tgt tta gg 55 ccg att cct tga gca ca 
HB-EGF Rev1 tgc cca act tca ctt tct ctt c 
NRG-Common Fwd gat cag caa att agg aaa tga cag 53 tct gaa gac aca tat gct cct 
NRG-Common Rev1 ggc ata cca gtg atg atc tcg 
NRG-GGF2 Fwd gct gcc act act gct gct g 70 cgg gga cga gta gca cac 
NRG-GGF2 Rev1 cgg gga cga gta gca cac 
NRG-SMDFsecSet Fwd aga acg ccc aag tca gca 5 atg gct tgt ccc agt g 
NRG-SMDF secSetRev1 ttg tcc cag tgg tgg atg ta 
NRG2 Fwd ttc gca tca aat atg gca ac 39 gac ggt gtc ctt ccc c 
NRG2 Rev1 ggc ctc gca gac ata ctc c 
NRG3 Fwd gcc agt ctg tca aac acc ac 26 cca cct agc cta ctt cgg 
NRG3 Rev1 atg gag cat gcc act tct tt 
NRG4 Fwd ggg gct ttg tta tgt gat acc t 23 ctg gag cct ggg aga a 
NRG4 Rev1 cct gta tag ttt tca acg cac ct 
BCL2 Fwd agg tgc atc tgg tga tgt ga 26 cac tcc aac ccc cga tct 
BCL2 Rev1 cac tcc aac ccc cga tct 
G6PDH secSet Fwd aga gac cgt gga tgc tga ag 65 ctc cgc act gct gac a 
G6PDH secSet Rev1 tga gga cct ccg tca gat g 
beta-Aktin Fwd att ggc aat gag cgg ttc 11 atg tcc acg tca cac ttc at 
beta-Atkin Rev gga tgc cac agg act cca t 
ER-Fwd aac cag tgc acc att gat aaa a 69 att ctc cct cct ctt cgg 
ER-Rev tcc tct tcg gtc ttt tcg tat c 
PGR-Fwd ttt aag agg gca atg gaa gg 11 ttt ttc tgc gga ttt tat caa 
PGR-Rev cgg att tta tca acg atg cag 
PTEN-Fwd gca caa gag gcc cta gat ttc 60 aat aca cat agc gcc tct ga 
PTEN-Rev cgc ctc tga ctg gga ata gt 
PIK3CA-Fwd cga gat cct ctc tct gaa atc ac 2 gaa ttt cgg gga tag tta cac aa 
PIK3CA-Rev gaa ttt cgg gga tag tta cac aa 
PIK3R1 Iso 1-Fwd aat gaa cga cag cct gca c 16 cag tac cat tca gca tct tgt aa 
PIK3R1 Iso 1-Rev ccg ttg ttg gct aca gta gta gg 
AKT common-Fwd ggc tca ccc agt gac aac tc 41 agc agc ttc agg tac tca aa 
AKT common-Rev act caa act cgt tca tgg tca c 
SRCcom-Fwd cga gaa agt gag acc acg aa 34 gtt gag gcc ctt ggc 
SRCcom-Rev ttg gcg ttg tcg aag tca 
SCUBE2-Fwd gct gcc atc cac agt aca ag 17 gac agt gtc ctc tcg ctc caa 
SCUBE2-Rev gac agt gtc ctc tcg ctc caa 
Ki-67-Fwd tga att tcc aag aaa aat acg tga 36 agc ttt ctc atc agg gtc a 
Ki-67-Rev tca ggg tca gaa gag aag cta ga 
Cyclin B1-Fwd cgc ctg agc cta ttt tgg t 34 aga aag cct gac aca ggt c 
Cyclin B1-Rev gca cat cca gat gtt tcc att 
HNF3α-Fwd agg gct gga tgg ttg tat tg 1 atg ttg ctg acc ggg a 
HNF3α-Rev acc ggg acg gag gag tag 
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Biomarker Primersequence (5' -> 3'-direction) Probe No. Reverse Primer RT 
Survivin com-Fwd ctt gaa agt ggc acc aga gg 29 cct cac ttc tca cct ggt aa 
Survivin com-Rev caa aaa tga gcc ccc aaa a 
TRIP13-Fwd ctc atg cgc tgt atg tcc a 65 gca agc ttc ttt ctc tct tca 
TRIP13-Rev gtc cac tgc cag aga cag g 
HPRT-Fwd tga cct tga ttt att ttg cat acc 73 aat gtg atg gcc tcc ca 
HPRT-Rev cga gca aga cgt tca gtc ct 
PBGD common-Fwd agc tat gaa gga tgg gca ac 25 gcc tgc atg gtc tct tgt a 
PBGD common-Rev ttg tat gct atc tga gcc gtc ta 
PPP1CA common-Fwd cct ata aga tca agt acc ccg aga 15 cag ttg aag cag tca gtg aa 
PPP1CA common-Rev gat gtt gta gcg tct ctt gca c 
IGF1 Fwd tgt gga gac agg ggc ttt ta 67 cac tca tcc acg atg cct 
IGF1 Rev atc cac gat gcc tgt ctg a 
IGF2 Fwd gct ggc aga gga gtg tcc 10 cat tgg gat tcc cat tgg 
IGF2 Rev gat tcc cat tgg tgt ctg ga 
IGF-1R Fwd ttc agc gct gct gat gtg 10 caa gtt ccc ggc tca tg 
IGF-1R Rev ggc tca tgg tga tct tct cc 
IGF-2R Fwd cag acc aca tat acc acg agg a 1 agt tga gag aaa aga tgg ggt 
IGF-2R Rev aga aaa gat ggg gtg gct gt 
 
Table 3. Antibodies employed in the study 
Antigen Source Order No. Dilution Method / System Pretreatment Incubation 
EGFR Ventana/Roche 790-2988 ready to use Ventana /3,3`-diamino-benzidine kit1 20 min, Protease 32 min 
HER2 Ventana/Roche 800-2996 ready to use Ventana /3,3`-diamino-benzidine kit1 30min, CC1 16 min 
IGF-1R Ventana/Roche 790-4346 ready to use Ventana /3,3`-diamino-benzidine kit1 60 min, CC1 28 min 
ER Ventana/Roche 790-4325 ready to use Ventana /3,3`-diamino-benzidine kit1 60 min, CC1 28 min 
PR Ventana/Roche 790-4296 ready to use Ventana /3,3`-diamino-benzidine kit1 60 min, CC1 28 min 
CK 5/6 Ventana/Roche 760-4253 ready to use Ventana /3,3`-diamino-benzidine kit1 60 min, CC1 32 min 
1 (XT Ultra View DAB kit, Ventana Medical Systems, Tucson, Arizona) 
 
For quantitative PCR, 3.5 µl cDNA (50ng/µl) 
were added to 16.5 µl PCR Master Mix according to 
the manufacturer´s instructions (LightCycler® 480 
Probes Master, Roche). For all targets, uniform 
ThermoCycler running conditions were used. In brief, 
initial preincubation at 95°C for 5 minutes was 
followed by 45 cycles of 95°C for 10 seconds, 60°C for 
20 seconds and 72°C for 1 second. Gene expression 
profiles were generated on the LightCycler® 480 
Real-Time PCR System (Roche). 
A standard curve, consisting of diluted human 
reference RNA (Universal Human Reference RNA, 
Stratagene), was included for every RT reaction and 
subsequent RT-PCR. For a run to be accepted there 
had to be a valid negative control and an 
amplification efficiency of between 1.9 and 2.1. 
Expression data were normalized to five averaged 
HKG. All experiments were performed in duplicate 
and the results averaged. Calibrator based 
calculations were used to determine relative gene 
expression profiles [31].  
Immunohistochemical analysis 
IHC investigation for various surrogate markers 
was performed to substantiate the results of gene 
expression analysis and to identify basal-like breast 
carcinomas. Markers investigated included the RTK 
EGFR, HER2 and IGF-1R, the hormone receptors ER 
and PR, and the basal-like marker CK5/6 [32]. Whole 
FFPET sections cut at 3 µm were stained with a 
Ventana Benchmark XT autostainer (Ventana Medical 
Systems). Details of the antibodies and methods 
employed are given in Table 3.  
Slides were counterstained with haematoxylin 
(Ventana). System and isotype controls were 
included. IHC investigation for ER and PR and for 
HER2 was performed according to up-to-date 
histopathological guidelines and recommendations 
[28, 29]. 
Immunostaining for EGFR and IGF-1R was 
evaluated semiquantitatively with a scoring system 
similar to that established for HER2 (0: no 
membrane-specific staining, 1+: weak, incomplete cell 
membrane staining in <10% of cells, 2+: weak or 
moderate staining of the complete cell membrane in > 
10% of cells, 3+: strong, complete membrane staining 
in > 10% of cells. Immunostaining for CK 5/6 was 
evaluated according to the criteria of Dabbs et al. [33] 
(0: no staining, R: single cells stained, 1+: 5-30% of 
cells stained, 2+: >30-60% of cells stained, 3+: > 60% of 
cells stained). The scores 0 and R were considered 
negative, 1+ to 3+ positive. 
Statistical analysis 
Statistical evaluation was performed with the 
help of the statistics software SPSS (Chicago, USA) 
and R [34]. The Kolmogorov Smirnov test was used to 
test for normal distribution. The Mann-Whitney U test 
and Student's t-test were used to test for significant 
differences in gene expression between the postulated 
subtypes RTK-high and RTK-low. T-test for equality 
of means and Levene´s test for equality of variances 
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was applied to demonstrate the statistic independence 
of tumor samples with adjuvant and neoadjuvant 
chemotherapeutic treatment in context to the 
gene-expression analyses. The influence of clinical 
parameters on the gene expression profile was 
investigated by multivariate analysis on the basis of 
the Chi-square test and the Mann-Whitney U test. 
Correlation between variables was observed with 
Pearson respectively Spearman rank correlation 
analyses. Hierarchical cluster analysis was performed 
to identify subtypes within the study cohort. The 
3-year survival rate was analyzed with the 
Kaplan-Meier curve. 
Ethics approval and consent to participate 
Specimens and data were anonymized, and the 
need for consent was waived by the institutional 
ethics committee of the Medical Faculty of the Ludwig 
Maximilians University of Munich. 
Results 
Biomarker detection efficiencies within 
RT-PCR analyses  
In the present study 34 tumor associated 
biomarkers relevant for EGFR and IGF-1R families 
and related biomarkers of the downstream signaling 
as well as 5 HKG were analyzed. Expression profiles 
for all tumor samples could be obtained for 31 of the 
biomarkers and all five HKG.  
Differentiation of triple-negative tumors into 
two distinct subtypes on the basis of gene 
expression profiling of RTK associated 
biomarkers 
Hierarchical cluster analysis revealed a 
dichotomous differentiation pattern amongst the 
triple-negative tumors (Figure 1).  
The two subtypes were characterized by low 
(subtype RTK-low; N=15) and high (subtype 
RTK-high; N=14) gene expression of the biomarkers 
investigated. The corresponding relative gene 
expression values of each biomarker are shown in 
Table 4. 
Further statistical analysis confirmed significant 
differences in gene expression between the subgroups 
RTK-low and RTK-high for 16 of the 31 biomarkers 
evaluated (Table 4). Of particular interest were 
significant differences for 3 of the 6 analyzed RTK 
(HER4, p≤ 0.001; IGF-1R, p < 0,001; IGF-2R, p = 0.015; 
Figure 2).  
 
 
Figure 1. Pearson correlation – triple-negative breast cancer 
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Table 4. Differential biomarker expression in triple-negative tumors of the subtypes RTK-low and RTK-high 
Biomarker p TNBC subtype Mean 95 % CI Biomarker p TNBC subtype Mean 95 % CI 
PR 0.000 RTK-low 2.789 1.802 - 3.776 Amphiregulin 0.24 RTK-low 2.880 0.840 - 4.920 
RTK-high 17.582 5.256 - 29.908 RTK-high 4.610 2.122 - 7.278 
HER4 0.000 RTK-low 1.510 0.827 - 2.373 NRG-com 0.408 RTK-low 16.995 -16.498 - 50.488 
RTK-high 10.550 3.887 - 17.213 RTK-high 3.390 1.669 -5.111 
EGF 0.043 RTK-low 3.728 1.153 - 6.303 Ki-67 0.407 RTK-low 1.390 1.114 - 1.665 
RTK-high 18.825 4.383 - 33.267 RTK-high 1.628 1.069 - 2.186 
PI3K-R1iso 0.000 RTK-low 4.494 3.659 - 5.329 SRC-com 0.254 RTK-low 17.375 13.012 - 21.738 
RTK-high 12.392 8.023 - 16.762 RTK-high 22.269 14.142 - 30.397 
SCUBE2 0.003 RTK-low 5.696 3.953 - 7.439 Survivin-com 0.119 RTK-low 0.262 0.185 - 0.339 
RTK-high 22.497 9.788 - 35.206 RTK-high 0.3981 0.228 - 0.568 
BCL2 0.000 RTK-low 10.077 7.813 - 12.340 TRIP13 0.382 RTK-low 1.214 0.948 - 1.479 
RTK-high 34.702 26.705 - 42.699 RTK-high 1.035 0.690 - 1.381 
IGF-1R 0.001 RTK-low 1.424 0.876 - 1.971 Cyclin B1 0.425 RTK-low 0.92 0.738 - 1.102 
RTK-high 4.332 2.159 - 6.504 RTK-high 1.082 0.696 - 1.467 
IGF-2R 0.015 RTK-low 2.545 1.827 - 3.263 HER2 0.794 RTK-low 6.353 5.173 - 7.533 
RTK-high 3.493 2.980 - 4.007 RTK-high 6.093 4.299 - 7.888 
IGF2 0.004 RTK-low 0.376 0.224 - 0.976 HER3 0.798 RTK-low 6.324 5.258 - 7.389 
RTK-high 0.473 0.069-1.015 RTK-high 8.650 5.070 - 12.231 
HNF3-α 0.001 RTK-low 0.142 0.025-0.308 β-Cellulin 0.889 RTK-low 63.354 37.120 - 89.588 
RTK-high 0.306 0.135 - 0.477 RTK-high 60.973 35.728 - 86.218 
IGF1 0.000 RTK-low 31.943 25.742 - 38.143 HBEGF 0.446 RTK-low 3.408 1.849 - 4.968 
RTK-high 113.493 73.942 - 153.044 RTK-high 4.189 2.689 - 5.688 
ER 0.000 RTK-low 0.833 0.520 - 1.146 NRG-2 0.727 RTK-low 5.416 1.366 - 9.467 
RTK-high 2.554 1.452 - 3.656 RTK-high 4.651 2.572 - 6.730 
PTEN 0.000 RTK-low 3.704 2.278 - 5.129 AKT-com 0.311 RTK-low 4.606 3.578 - 5.633 
RTK-high 6.786 4.883 - 8.689 RTK-high 5.675 3.640 - 7.710 
Pi3K-CA 0.043 RTK-low 5.415 3.521 - 7.310 EGFR 0.257 RTK-low 23.781 -12.782 - 60.344 
RTK-high 8.481 6.383 - 10.579 RTK-high 3.645 2.668 - 4.621 
LEF1 0.003 RTK-low 0.871 0.684 - 0.106 TGF-α 0.219 RTK-low 3.587 1.112 - 6.062 
RTK-high 0.2561 0.131 - 0.381 RTK-high 5.865 2.817 - 8.913 
PI3K R1 iso 0.000 RTK-low 4.494 3.659 - 5.329      
RTK-high 12.392 8.023 - 16.762      
 
 
Figure 2. Differential gene expression by the triple-negative subtypes RTK-low und RTK-high in relation to PR, ER, HER4, IGF-1R and IGF-2R 
 
Interestingly, significant differences in gene 
expression patterns for ER (p = 0.001) and PR (p < 
0.001) were also found between the two subtypes 
(Figure 2). By contrast, all cases of triple-negative 
tumors, by definition lacked IHC staining for ER and 
PR. 
Correlation analysis was performed to 
determine whether the RTK and hormone receptors 
investigated are subject to functional interaction 
(Table 5).  
 
 Journal of Cancer 2018, Vol. 9 
 
http://www.jcancer.org 
2596 
Table 5. Correlation coefficients for RTK, ER and PR gene 
expression 
 ER PR EGFR egfr HER3 HER4 IGF-1R IGF-2R 
ER 1        
PR 0.654** 1       
EGFR 0.034 0.001 1      
HER2 0.057 -0.081 0.099 1     
HER3 -0.109 0.078 0.023 0.000 1    
HER4 0.675** 0.623** -0.021 -0.105 0.222 1   
IGF-1R 0.419* 0.555** -0.056 0.112 0.206 0.394* 1  
IGF-2R 0.293 0.284 0.519** -0.034 0.354 0.369* 0.264 1 
** p<0.005; * p<0.05 
 
Increased correlation, in particular for HER4 
with ER (r = 0.675; p≤0.001), HER4 with PR (r=0.623, 
p≤0.001), as well as IGF-1R with ER (r = 0.419; 
p=0.024) and IGF-1R with PR (r=0.555; p=0.002) was 
found (Figure 3). 
Additionally, we compared the patient survival 
based on the RTK-high and RTK-low gene signature. 
Kaplan-Meier analysis demonstrated superior 
three-year survival in the RTK-high group as opposed 
to the patients in the RTK-low group (three-year 
survival rate of 100% v. 60%; log-rank test, p-value = 
0.022; Figure 4). 
In summary, two subtypes of TNBC could be 
identified on the basis of gene expression profiles of 
16 biomarkers of the EGF and IGF receptor families 
and biomarkers of their downstream signaling as well 
as the hormone receptors ER and PR (Table 4). Of 
special interest are the RTK HER4 and IGF-1R, as well 
as the hormone receptors ER and PR, for which the 
findings of correlation analysis indicate functional 
interaction in cell signaling. 
Comparison of IHC and gene expression 
findings  
In order to determine to what extent the 
differences in gene expression between the subtypes 
RTK-high and RTK-low as detected by RT-PCR are 
also reflected at the protein level, IHC investigations 
were carried out for certain key proteins from the 
biomarker panel (IGF-1R and EGFR: study findings, 
HER2, ER and PR: findings of routine diagnostic 
 
 
Figure 3. Increased correlation between analyzed RTK and hormone receptors pictured in scatter plot charts A) HER4 and ER, B) HER4 and PR, C) IGF-1R and ER, D) IGF-1R 
and PR 
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work-up). For IGF-1R and EGFR the IHC findings 
were consistent with the gene expression data. 
Accordingly, differences in IGF-1R expression at both 
transcriptional and translational levels were found 
between the subtypes RTK-high and RTK-low (IHC: p 
Mann-Whitney U test = 0.005, RT-PCR: p Mann-Whitney U test < 
0.001; r Spearman-Rho = 0.706, p ≤ 0.001). The 
expression profile of EGFR in both subtypes of 
triple-negative tumors could also be confirmed at the 
IHC level (IHC: p Mann-Whitney U test = 0.377, RT-PCR: p 
t-test = 0.257; r Spearman-Rho = 0.311, p = 0.100).  
As shown in Table 1, each case in the study 
group exhibited a triple negative phenotype 
according to established histopathological criteria. 
However, there were highly significant differences in 
the gene expression profiles for both ER (p Mann-Whitney 
U test = 0.001) and PR (p Mann-Whitney U test ≤ 0.001) 
amongst the triple-negative tumors in relation to the 
postulated subtypes RTK-high and RTK-low. As with 
the IHC findings, no significant difference was found 
for HER2 at the transcriptional level between the 
postulated subtypes RTK-high and RTK-low (p t-test = 
0.794; r Spearman-Rho = -0.087, p = 0.655).  
Immunohistochemical characterization of 
basal-like subtypes  
In relation to the much debated question as to 
the extent to which triple-negative tumors correspond 
to the basal-like breast cancer subtype, and to 
determine to what extent one of the two 
triple-negative subtypes defined in the study 
correlates with the basal-like subtype, IHC staining 
for the basal-like tumor associated biomarker CK5/6 
and EGFR was performed. The IHC analyses revealed 
a basal-like phenotype within 79% of the 
samples. Statistical analysis did show no 
significant difference between the 
triple-negative subtypes defined in this study 
on the basis of gene expression analyses and 
the basal-like and non-basal-like TNBC 
subtypes (p Pearson Chi-Square test = 0.080).  
Comparison of clinical parameters and 
genetic expression of tumor-related 
biomarkers  
By means of multivariate analysis the 
variables nodal status, age, tumor size and 
angiosis carcinomatosa were tested for a 
possible relationship to biomarker 
expression and subtype (RTK-high and 
RTK-low). The Chi-square test and 
Mann-Whitney U test failed to show a 
significant relationship between any of the 
clinicopathological parameters and the 
subtypes. 
T-test for equality of means and 
Levene’s test for equality of variances demonstrated 
the statistic independence of tumor samples with 
adjuvant and neoadjuvant chemotherapeutic 
treatment in context to the RTK gene-expression 
analyses (Table 6). None of the changes was 
significant after Bonferroni correction. 
Discussion 
Characterization and subtyping of 
triple-negative tumors based on 
therapeutically relevant RTK 
The search for individualized treatment 
strategies in recent years has revealed biomarkers 
with predictive relevance for a large number of 
malignancies. This information has been applied to 
the development of individualized tumor therapies. 
The various RTK are of special importance here, 
particularly representatives of the EGF and IGF 
receptor families which, in the case of overexpression, 
represent target proteins for individualized tumor 
therapy for an increasing number of tumor entities.  
In the case of breast cancer, too, gene expression 
data and IHC findings have characterized patients for 
whom target-specific therapy is suitable. A number of 
clinical trials are concerned with the question as to 
what extent inhibition of EGFR or IGF-1R by specific 
monoclonal antibodies or RTKI can benefit patients 
with advanced breast cancer [35, 36, 37, 38, 39]. The 
combination of chemotherapy with EGFR inhibition 
appears so far to have mixed results. Adequate results 
of an individual therapeutic IGF-1R inhibition are not 
yet available. 
 
Figure 4. Overall survival of patients with RTK-high and RTK-low gene signature 
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Table 6. Statistic independence of tumor samples with adjuvant and neoadjuvant chemotherapeutic treatment in context to the RTK 
gene-expression analyses 
Biomarker Fold Change  
(neoadjuvant versus adjuvant) 
p-value (Welch) 
 
p-value (Levene) Biomarker Fold Change 
(neoadjuvant versus adjuvant) 
p-value (Welch) p-value (Levene) 
PR -1.847 0.269 0.212 PI3K_R1iso -1.589 0.078 0.607 
ER -1.145 0.755 0.254 AKT_com 1.176 0.325 0.478 
EGFR -1.022 0.960 0.158 SRC_com -0.114 0.511 0.780 
HER2 1.135 0.393 0.834 SCUBE2 -0.135 0.515 0.222 
Her3 -1.009 0.970 0.777 BCL2 -1.712 0.081 0.915 
Her4 -1.170 0.804 0.376 IGF-1R -1.454 0.390 0.690 
TGF_alpha -1.079 0.817 0.943 IGF-2R -1.403 0.090 0.250 
EGF -2.634 0.150 0.604 IGF1 -1.557 0.234 0.477 
ß_Cellulin -1.125 0.826 0.279 IGF2 -1.297 0.729 0.605 
Amphiregulin -1.945 0.259 0.482 HNF3-alpha -1.842 0.318 0.046 
HB_EGF 1.183 0.573 0.924 Survivin com -1.600 0.117 0.765 
NRG_com -1.506 0.531 0.962 TRIP 13 1.044 0.794 0.256 
NRG_2 0.140 0.348 0.153 CyclinB1 -1.159 0.386 0.151 
PTEN -1.546 0.102 0.881 Ki-67 1.037 0.840 0.161 
PI3K_CA -1.242 0.385 0.274 LEF1 -1.855 0.041 0.973 
PI3K_R1com -1.558 0.082 0.233     
 
At the same time, it has been shown in recent 
years that despite the importance of single 
tumor-relevant biomarkers, the neoplastic behaviour 
of tumors is influenced by numerous interactions in 
downstream signaling. The crosstalk of various 
overexpressed RTK, hormonal transcriptional 
regulation (ER) or mutational, constitutive activation 
in downstream signaling (EGFR, KRAS) represent 
multifactorial mechanisms involved in tumor growth. 
Because of the complexity of the situation, more 
recent clinical trials have focused increasingly on 
combination treatment strategies in narrowly defined 
patient groups. The characterization of breast tumors 
using a panel of tumor-specific surrogate markers not 
only contributes to a better understanding of 
functional mechanisms involved in tumor 
differentiation, growth and invasion, but also 
represents a basis for new combination treatment 
strategies. In addition, exact subtyping of breast 
cancer cases such as luminal A, luminal B, normal 
breast-like, ERBB2-overexpressing and basal-like 
molecular subtypes of breast cancer is still used for 
optimal patient selection in clinical trials.  
In the study presented, we examined gene 
expression levels of various RTK and related 
biomarkers in TNBC without individualized 
treatment options with the aim of defining 
heterogeneous expression patterns and possible 
TNBC subtypes. Hierarchical cluster analysis was able 
to identify a panel of biomarkers that allows two 
distinct subtypes of TNBC to be distinguished. 
Further analysis of the genetic cluster emphasizes in 
particular the significance of the two RTK IGF-1R and 
HER4, as well as the hormone receptors ER and PR. 
Cases with overexpression of these markers described 
above (RTK-high) represent a potentially interesting 
group for clinical investigations. In addition, the 
possibility to identify those breast cancer patients who 
are potential responders for personalized medicine 
targeting IGF-1R or ER is of particular significance. 
Differentiation of triple-negative tumors into 
basal-like positive and negative subtypes 
Several microarray-based studies have 
demonstrated a differentiation of breast cancer into at 
least 5 different subtypes [40, 41, 42, 43]. Selected gene 
sets for around 500 biomarkers enable subtyping of 
breast carcinoma into luminal A, luminal B, normal 
breast-like, ERBB2-overexpressing and basal-like 
tumors. Tumors with the basal-like phenotype which 
are characterized by, among other features, by the 
absence of IHC ER and HER2 expression, are of 
particular clinical interest. Scientific studies 
employing IHC techniques and gene expression 
analysis have shown that up to 15% of all breast 
cancers exhibit the basal-like subtype [32, 33]. 
Numerous studies have attempted to equate 
triple-negative tumors with basal-like breast cancer, 
and indeed an accumulation of the basal-like 
phenotype amongst triple-negative tumors has been 
documented. Nevertheless, it has been shown that the 
two are not identical with each other [44]. 
Comparative analysis has shown that, although 
triple-negative tumors (immunohistochemically 
defined) often show a basal-like phenotype, and 
tumors diagnosed as basal-like breast cancer (on the 
basis of gene expression) are predominantly 
triple-negative, the two categories are up to 30% 
discordant [19, 45].  
Methods for the identification of the basal-like 
phenotype rely mainly on the detection of expression 
of proliferation-specific biomarkers by gene 
expression analysis and immuno-histochemical 
techniques. Our study utilized IHC staining for CK 
5/6. Eighty-one percent of the tumor samples were 
found to express a basal-like phenotype, a prevalence 
consistent with figures quoted in the literature.  
 Journal of Cancer 2018, Vol. 9 
 
http://www.jcancer.org 
2599 
In our study, comparison of the subtypes 
RTK-high and RTK-low and the group classed as CK 
5/6 positive revealed no significant correlation. 
Therefore, on the basis of our findings it can be 
assumed that this is a newly defined and independent 
gene expression signature that permits further 
subtyping of TNBC into RTK-high and RTK-low 
genotypes. 
Gene expression of ER in triple-negative breast 
cancer 
IHC analysis of the hormone receptor status, is 
one of the standardized clinical investigations used in 
the diagnostic work-up of patients with breast cancer 
for treatment prediction. Selection of the cases for our 
study was based upon the findings of routine 
histopathological investigations. By definition, all 
exhibited a negative (<1%) IHC score for ER and PR. 
By contrast, our gene expression analysis revealed 
over-expression of ER and PR in some cases, there 
being a highly significant difference between the 
subtypes RTK-high and RTK-low. The discrepancy 
may be due to the increased sensitivity of RT-PCR. 
Differences in regulation of protein expression at the 
translational level are also conceivable. 
The results of correlation analysis pertaining to 
IGF-1R, HER4 and ER in tumors with the RTK-high 
genotype suggest that these receptors interact with 
each other through regulatory mechanisms. Hence, 
further in-vivo investigations, especially into the 
potential of new immunotherapeutic approaches 
using combined immunotherapeutic approaches in 
TNBC patients with the RTK-high genotype, would 
be of great interest [46, 47, 48].  
Crosstalk between IGF-1R and ER signaling 
Recent studies have shown that there is crosstalk 
in cell signaling between RTK and ER. Various 
different trans-activating mechanisms with 
stimulating effects on the downstream signaling of 
adjacent RTK and ER were generally found [49, 50]. 
IGF-1R is one of the most important 
representatives of the IGF receptor family and, like 
ER, is associated with neoplastic properties when 
overexpressed [51, 52, 53]. 
In our study we found increased expression of 
IGF-1R and ER in TNBC of the RTK-high subtype. In 
addition, strong correlation between IGF-1R and ER 
was seen, which suggests functional interaction 
between the two receptors. As shown in recent 
studies, IGF-1R and ER are able to trans-activate each 
other and lead to activation or enhancement of 
downstream signaling [52]. In addition, in vivo 
experiments have demonstrated their combined 
significance in tumorigenesis [54]. 
In studies of IGF-1R-mediated ER activation [55, 
56, 57] it has been shown that tyrosine kinases 
involved in IGF-1R downstream signaling, such as 
MAPK, RSK and AKT, are able to phosphorylate and 
activate ER at the AF-1 domain (Serin118, Serin167). 
Furthermore, in vivo experiments showed that IGF-1 
is able to increase the expression of PR, an estrogen 
response element. 
In addition to IGF-1R-mediated ER 
phosphorylation and activation, effects of ER on 
IGF-1R signaling have also been demonstrated [47]. 
ER is able, by means of various different regulatory 
mechanisms, to impact on IGF-1R downstream 
signaling. Studies have shown that anti-estrogens like 
tamoxifen can inhibit IGF-mediated growth [58]. 
Thus, it has been demonstrated that estrogens are able 
to regulate IGF-1R at the transcriptional level and to 
transactivate IGF-1R by phosphorylation. ER belongs 
to the steroid hormone receptor family and functions 
primarily as a transcription factor. IGF-1R is one of the 
most important estrogen response elements [58]. 
Besides the ability of ER to inactivate inhibitory 
elements of IGFR signaling, such as IGFBP-3, binding 
of ER to Shc with subsequent phosphorylation of 
MAPK have also been described. In addition to the 
singular importance of hormone receptors as a 
therapeutic target, several studies have demonstrated 
the existence of complex regulatory mechanisms and 
interactions in downstream signaling between ER/PR 
and growth factors [59, 60]. Several clinical trials 
concerning the combined use of IGF-1R and 
ER-inhibitors are under investigation [61, 62].  
Crosstalk between HER4 and ER signaling 
The c-erbB-4 gene (HER4) belongs to the EGFR 
family. Little is known about the functional 
significance of HER4 in the pathogenesis of breast 
cancer. In normal breast tissue, its functions include 
the differentiation of myocardial cells and mammary 
epithelial cells and the development of the central 
nervous system [63, 64]. Compared to the most 
important representatives of the EGFR family, EGFR 
and HER2, the prognostic impact of HER4 expression 
in breast cancer are basically unclear and 
controversially discussed [65, 66]. Unlike the 
remaining members of the EGF receptor family, 
which act primarily as mitogenic effectors in breast 
cancer cells, HER4 appears to have a large number of 
different functions in normal and neoplastic breast 
tissue. With regard to the overexpression of HER4, 
experimental studies have shown both oncogenic and 
tumor suppressive functions [67, 68]. Other 
investigations have also shown that HER4 is generally 
associated with differentiated and less aggressive 
tumors, and that it correlates with a better prognosis 
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and a longer disease-free interval [66, 69, 70]. In 
addition, it has been shown that breast cancer patients 
who exhibit coexpression of HER4 and ER have a 
lower recurrence rate [71] and a higher survival rate 
[72] than those who express ER alone.  
Interestingly, several in vivo and in vitro studies 
have shown a strong correlation and crosstalk 
between HER4 and ER expression in breast cancer [68, 
73, 74]. Intense efforts to elucidate mechanism of 
crosstalk between HER4 and ER could identify an 
autocrine HER4/ER signaling pathway where the 
factor HER4 intracellular domain (4ICD), a cleavage 
product of HER4, acts as transcriptional coregulator 
of ER [73, 75, 76, 77, 78]. 
Our results point to an increased rate of 
coexpression of HER4 and ER in triple-negative 
tumors with the RTK-high phenotype. The 
coexpression of HER4 and ER suggests the existence 
of crosstalk in downstream-signaling within defined 
subpopulations of breast cancer patients. 
ER / RTK crosstalk– development of intrinsic 
and acquired resistance  
Antihormonal therapy (tamoxifen, anastrozole) 
and HER2 inhibition (trastuzumab, lapatinib) 
represent important cornerstones in personalized 
therapy for the treatment of breast cancer in women 
with overexpression of the corresponding receptors. 
Further promising targets for individualized therapy 
the RTK EGFR and IGF-1R and targeting the PI3K-Akt 
pathway are currently subject of several studies and 
clinical trials [79, 80, 81, 82]. However, follow-up 
studies did show the development of resistance in 
some patients receiving antihormonal therapy and/or 
RTK inhibitors.  
Studies have demonstrated intrinsic or acquired 
resistance to treatment with tamoxifen in 20-30% of 
hormone-receptor-positive breast cancer patients [83]. 
Although the mechanisms involved have not yet been 
clarified in detail, it appears that, in addition to 
coregulatory and epigenetic mechanisms, 
transactivating processes between RTK and ER could 
be responsible [80, 84]. Further investigations have 
revealed complex co-operation of genomic and 
non-genomic/fast ER signaling and their crosstalk 
with growth factor receptors, such as EGFR, HER2, 
HER4 or IGF-1R, in the development of endocrine 
resistance [85, 86, 87]. In brief, activated cytoplasmic 
and membrane-bound ER show the ability to 
stimulate RTK, either directly via adaptor proteins 
like Shc, or indirectly by nuclear ER through increased 
release of RTK-specific ligands, for example HB-EGF. 
Following subsequent activation of the downstream 
signaling kinases MAPK and AKT, phosphorylation 
and thus activation of nuclear ER occurs, which leads 
to increased gene expression, including the expression 
of RTK-related genes. Thus, innovative treatment 
strategies aim at inhibition of both RTK and ER. 
Current indications for hormone receptor 
therapy are based on standardized IHC findings of 
routine diagnostic investigations. According to the 
histopathological guidelines and recommendations 
[28], antihormonal treatment is indicated when more 
than 1% of the tumor cells are ER and/or PR positive. 
Large overviews of randomized clinical trials have 
confirmed the therapeutic value of antihormonal 
treatment only in immunreactive ER-positive breast 
cancers.  
Our investigations demonstrated a significant 
increase in ER gene expression level in a newly 
characterized subtype (RTK-high) of TNBC. In 
addition, correlation analysis suggests functional 
interaction between IGF-1R, HER4 and ER. It is not 
yet clear to what extent antihormonal therapy would 
be effective in tumors in which hormone receptor 
status is negative by immunohistochemistry but gene 
expression is elevated. However, on the basis of 
crosstalk between ER and RTK, it is conceivable that a 
combination of inhibition of both ER and 
corresponding RTK, like IGF-1R or HER4, could be of 
benefit. 
Conclusions 
RTK-associated gene expression profiles 
generated in this study revealed dichotomous 
differentiation within the triple-negative study group. 
IHC analysis verified this at the posttranslational 
level. Correlation analysis of the biomarkers 
investigated suggests a functional connection 
between IGF-1R, IGF-2R, HER4, PR and ER. Based on 
survival analysis the differentiation of triple-negative 
tumors with RTK-high and RTK-low gene signature 
seems to be from prognostic relevance. 
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